ClinicalTrials.gg
CompletedNCT02183350Updated Jul 8, 2014

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

A Phase 1 interventional study of BI 1356 BS - single rising dose and Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
47th of 67
47 · median 175
Started
2005
with 1 other
Phase 1
7 of 67
none open now
Registered
44th of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 47th largest by enrollment, is one of 2 that started in 2005, is one of 7 in phase 1, and was the 44th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 21 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The primary objective of the current study was to investigate the safety and tolerability of BI 1356 BS following administration of multiple rising oral doses of 1 mg, 2.5 mg, 5 mg, and 10 mg over 12 days in male patients with type 2 diabetes.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male patients with proven diagnose of type 2 diabetes mellitus treated with diet and exercise only or with one (or two) oral hypoglycaemic agents besides glitazones

  • Glycosylated A1 ()

    • ≤ 8.5 % at screening for patients treated with diet and exercise and/or one oral hypoglycaemic agent or
    • ≤ 8.0 % at screening for patients treated with two oral hypoglycaemic agents
  • Age ≥21 and Age ≤65 years
  • ≥18.5 and BMI ≤35 kg/m2 (Body Mass Index)
  • Caucasian ethnicity
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice GCP and the local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate (PR) and (ECG)) deviating from normal and of not acceptable clinical relevance
  • concomitant diseases like renal insufficiency, cardiac insufficiency (NYHA) II-IV, known cardiovascular diseases including hypertension > 160/110 mmHg, stroke and (TIA)
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders besides type 2 diabetes, hyperlipidaemia and medically treated hypertension
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders besides polyneuropathy
  • Chronic or relevant acute infections (e.g. (HIV), Hepatitis)
  • History of relevant allergy/ (including allergy to drug or its )
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial except allowed co-medication
  • Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  • Participation in another trial with an drug within two months prior to administration or during the trial
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of not acceptable clinical relevance
  • Change of drug dosing of allowed co-medication (anti-hypertensive agents, acetylic salicylic acid and statins) within the last 3 months
  • Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval > 120 ms or > 450 ms or QT >500 ms
  • Fasted blood glucose > 240 mg/dl (=13.3 mmol/L) on two consecutive days during washout
  • Serum creatinine above at screening
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
47 participants (actual)

Study arms

  • Experimental
    BI 1356 BS - single rising dose

    Drug: BI 1356 BS - single rising dose

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events

    Time frame: up to 28 days

  2. Number of patients with abnormal findings in physical examination

    Time frame: up to 28 days

  3. Number of patients with abnormal changes in Vital signs (blood pressure (BP), pulse rate (PR))

    Time frame: up to 28 days

  4. Number of patients with abnormal changes in 12-lead ECG (electrocardiogram)

    Time frame: up to 28 days

  5. Number of patients with abnormal changes in laboratory parameters

    Time frame: up to 28 days

  6. Assessment of tolerability by investigator on a 4-point scale

    Time frame: up to 28 days

Secondary outcomes

  1. Cmax (maximum concentration of the analyte in plasma)

    Time frame: predose, up to 456 h

  2. tmax (time from dosing to maximum concentration)

    Time frame: predose, up to 456 h

  3. AUC (area under the concentration-time curve of the analyte in plasma)

    Time frame: predose, up to 456 h

  4. Ae (amount of analyte that is eliminated in urine)

    Time frame: predose, up to 456 h

  5. fe (fraction of analyte excreted in urine)

    Time frame: up to 288 h

  6. CLR (renal clearance of the analyte in plasma)

    Time frame: up to 288 h

  7. Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval)

    Time frame: predose, up to 456 h

  8. Cpre,N (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose N)

    Time frame: predose, up to 456 h

  9. λz,ss (terminal rate constant in plasma at steady state)

    Time frame: predose, up to 456 h

  10. t1/2,ss (terminal half-life of the analyte in plasma at steady state)

    Time frame: predose, up to 456 h

  11. MRTpo,ss (mean residence time of the analyte in the body after 12 administrations at steady state)

    Time frame: predose, up to 456 h

  12. CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)

    Time frame: predose, up to 456 h

  13. Vz/F,ss (apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state)

    Time frame: predose, up to 456 h

  14. Changes in PTF (peak trough fluctuation)

    Time frame: up to 28 days

  15. RA,Cmax based on Cmax

    Time frame: predose, up to 456 h

  16. RA,AUC based on AUCτ

    Time frame: predose, up to 456 h

  17. Changes in Dipeptidyl-Peptidase IV (DPP-IV) activity in plasma

    Time frame: predose, up to 456 h

  18. Change in plasma glucose levels

    Time frame: up to 13 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005 and a primary completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Apr 2005
Primary completionActual
Aug 2005
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183350
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Apr 2005
Primary completion
Aug 2005
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion